Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.36 - $7.60
Previous CloseN/A
Volume8.30K
Average Volume (3M)4.41K
Market Cap
$152.24M
Enterprise Value$1.32M
Total Cash (Recent Filing)$114.49M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding40,374,640
10 Day Avg. Volume2,527
30 Day Avg. Volume4,408
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue1.94
Enterprise Value/Gross Profit1.94
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$8.33Price Target Upside124.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMOLN ended 2Q25 with CHF 114.5M in cash and equivalents, extending the cash runway into 2028.
LeadershipThe appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer is highlighted as a notable update.
Product DevelopmentThe company's investment thesis focuses on MP0712 as a promising radiopharmaceutical candidate in the DLL3 space.
Bears Say
Regulatory DelaysMOLN reported a minor delay to the planned MP0712 study, with the IND submission now expected in 3Q25 instead of mid-2025.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.36 and its highest was $7.60 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $152.24M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 18, 2026 which is in 160 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2025. The company reported -$0.684 earnings per share for the quarter, missing the consensus estimate of -$0.474 by -$0.21.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.684 in its last earnings report, missing expectations of -$0.474. Following the earnings report the stock price went down -7.82%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
Molecular Partners Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.33 (124.53% Upside)
$8.33 (124.53% Upside)
Blogger Sentiment
Bullish
MOLN Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.29%
12-Months-Change
Fundamentals
Return on Equity
-48.90%
Trailing 12-Months
Asset Growth
-17.79%
Trailing 12-Months
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$8.33
▲(124.53% Upside)
Technical Analysis
Compugen
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---